<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Introduction of new agents for the treatment for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) has been accompanied by the publication of guidelines </plain></SENT>
<SENT sid="1" pm="."><plain>The COLCHIC cohort was set up to evaluate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> treatment practices and the use of these innovative and expensive agents </plain></SENT>
<SENT sid="2" pm="."><plain>Patients initiating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> treatment at the Bordeaux teaching hospital between 1 March 2005 and 1 March 2006 were identified, and treatment courses from 1 March 2005 to 31 December 2006 were studied; 192 patients were included, 188 with analysable data: 43 patients initiated 51 courses for non-<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e>, 153 initiated 366 courses for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e>, eight patients initiated courses for both non-metastatic and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Most treatments were used for indications found in guidelines published during the study (83.9%) </plain></SENT>
<SENT sid="4" pm="."><plain>Of the others, nearly half were approved in guidelines published subsequently </plain></SENT>
<SENT sid="5" pm="."><plain>In this teaching hospital, prescribing practice was generally in line with recommendations, with an anticipation of future guidelines </plain></SENT>
<SENT sid="6" pm="."><plain>This mostly concerned monoclonal antibodies, which were new at the time of the study </plain></SENT>
</text></document>